Your browser doesn't support javascript.
loading
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Doi, Toshihiko; Yoshino, Takayuki; Shitara, Kohei; Matsubara, Nobuaki; Fuse, Nozomu; Naito, Yoichi; Uenaka, Kazunori; Nakamura, Takashi; Hynes, Scott M; Lin, Aimee Bence.
  • Doi T; aDepartment of Gastrointestinal Oncology bDepartment of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba cEli Lilly Japan K.K., Kobe, Japan dEli Lilly and Company, Indianapolis, Indiana, USA.
Anticancer Drugs ; 26(10): 1043-53, 2015 Nov.
Article en En | MEDLINE | ID: mdl-26288133

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Quinasas / Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Proteínas Quinasas / Neoplasias Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Quinasas / Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Proteínas Quinasas / Neoplasias Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article